Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
9Customers
2Debt Items
0Related Chains
Source-Backed Evidence Depth
BioAtla, Inc. (BCAB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
15Total relationships
2Distinct source URLs
8High confidence
0.767Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
BioAtla, Inc. Suppliers
Ticker
Name
Confidence
Evidence
INVERSAGEN-LLC
INVERSAGEN-LLC
92%
BioAtla entered into an exclusive license agreement with Inversagen, LLC, as amended in July 2020, in which BioAtla granted Inversagen, LLC an exclusive, worldwide, royalty-bearing license under cert…
BEONE
BEONE
90%
As consideration for this amendment, the Company agreed to pay BeOne mid-single digit royalties on sales worldwide
HIMALAYA-THERAPEUTICS-SEZC
HIMALAYA-THERAPEUTICS-SEZC
80%
the Company also entered into an agreement with Himalaya Therapeutics SEZC, a related party
BioAtla, Inc. Customers
Ticker
Name
Confidence
Evidence
CONTEXT-THERAPEUTICS-INC
CONTEXT-THERAPEUTICS-INC
95%
Under the terms of the Context License Agreement, BioAtla granted Context an exclusive, worldwide license to develop, manufacture and commercialize two licensed antibodies
INVERSAGEN-AI-LLC
INVERSAGEN-AI-LLC
90%
Inversagen AI has agreed to purchase an additional 30.625% of the SPV common units in exchange for $35 million
BIOATLA-HOLDINGS-LLC
BIOATLA-HOLDINGS-LLC
62%
If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product cou…
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product cou…
HIMALAYA-THERAPEUTICS-LIMITED-COMPANY
HIMALAYA-THERAPEUTICS-LIMITED-COMPANY
62%
power outage or other event prevented us from using all or a significant portion of our headquarters, damaged critical infrastructure, such as our research facilities or the manufacturing facilities …
HIMALAYA-THERAPEUTICS-SEZC-INVERSAGEN-LLC
HIMALAYA-THERAPEUTICS-SEZC-INVERSAGEN-LLC
62%
If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product cou…
INVERSAGEN-LLC
INVERSAGEN-LLC
62%
If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product cou…
SPV-LLC
SPV-LLC
62%
under the Context License Agreement comprised of BioAtla’s promise to transfer the License. Context is responsible for developing BA3362 and for global regulatory filings and commercialization. Conte…
YA-II-PN-LTD
YA-II-PN-LTD
62%
ring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): As of March 31, 2026 Level 1 Level 2 Level 3 Total Assets Cash equivalents $ 1,689…
BioAtla, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BCAB-DEBT-8089
Warrants outstanding: 59.5
90%
xbrl warrant detail from xbrl 2026-03-31.
BCAB-DEBT
Debt stack $6.1M
90%
Market cache reports total debt of $6.1M.
BioAtla, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for BioAtla, Inc..
BioAtla, Inc. Ownership
Holder
Name
Confidence
Evidence
BCAB-OWNER-ACORN-CAPITAL-ADVISORS-LLC
ACORN CAPITAL ADVISORS, LLC
90%
13F overlay lists ACORN CAPITAL ADVISORS, LLC as top holder; 35 tracked holders.
BioAtla, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
